Viridian Reports Q3 2026 Financial Results, Highlights Lumvoa Net Product Revenue
Viridian reported $24.7M in Lumvoa net product revenue with 100+ patients on therapy in Q3 2026. The company currently holds $955.2M in cash and announced the initiation of a phase 1 trial for VRDN-292 in Q4 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed